Detalhe da pesquisa
1.
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 602(7897): 503-509, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35110735
2.
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature
; 558(7709): 307-312, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29849141
3.
Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 612(7941): E22, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477542
4.
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Mol Ther
; 26(1): 269-279, 2018 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203150
5.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Blood Cancer Discov
; 4(2): 118-133, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413381
6.
PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response.
Front Immunol
; 13: 872756, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603165
7.
Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.
J Am Acad Dermatol
; 75(5): 1054-1057, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745631
8.
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
J Clin Invest
; 131(16)2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34396987
9.
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma.
Oncoimmunology
; 9(1): 1676615, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002286
10.
CRISPR-engineered T cells in patients with refractory cancer.
Science
; 367(6481)2020 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32029687
11.
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Nat Med
; 24(5): 563-571, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29713085
12.
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Nat Med
; 27(3): 561, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547459
13.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med
; 21(8): 914-921, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26193344
14.
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Sci Transl Med
; 5(197): 197ra103, 2013 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23926201